ACC-001

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
012320082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVES Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid- beta therapeutic vaccine, was… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2016
2016
Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy that aims to reduce brain… (More)
Is this relevant?
2016
2016
BACKGROUND ACC-001 is an investigational therapeutic vaccine designed to elicit antibodies against the N-terminal peptide 1-7 of… (More)
Is this relevant?
2016
2016
BACKGROUND Vanutide Cridificar (ACC-001), a novel investigational immunotherapeutic vaccine designed to elicit antibodies against… (More)
Is this relevant?
2015
2015
OBJECTIVE Multiple lines of evidence indicate that pathological accumulation of amyloid beta (Aβ) peptide in the brain is linked… (More)
Is this relevant?
Review
2015
Review
2015
Active or passive immunotherapy is expected to slow or stop the pathological process of Alzheimer's disease (AD). Immunotherapy… (More)
Is this relevant?
Review
2014
Review
2014
Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated… (More)
Is this relevant?
Review
2014
Review
2014
PURPOSE OF REVIEW We reviewed clinical trials on active and passive anti-β-amyloid (Aβ) immunotherapy for the treatment of… (More)
Is this relevant?
Review
2009
Review
2009
We would like to clarify and update information in the review article by Wilcock and Colton recently published in JAD [1]. In… (More)
Is this relevant?
Review
2008
Review
2008
BACKGROUND In a phase 2a clinical trial of AN1792 (Study 201), a potential immunotherapeutic agent for use in Alzheimer's disease… (More)
Is this relevant?